Combinatorial treatment with anti-CD25 and anti-CTLA-4 could be applied to the E6-RHDV-VLP-PADRE vaccination regimen, particularly as a good therapeutic outcome with the antibodies used in combination has been shown in models of mouse melanoma [69], colon carcinoma [70] and previously in the TC-1 HPV model [55]. Here, CTLA4 is linked to melanoma.